Network-meta analysis of 9 kinds of patent Chinese medicine for nourishing qi and activating blood in the treatment of angina pectoris of coronary heart disease

Objective:To evaluate the efficacy and safety of Yiqi Huoxue oral Chinese patent medicine in the treatment of angina pectoris.Methods:the databases of EMBASE,PubMed,CNKI,Wanfang and VIP were searched by computer,and the randomized controlled trial(RCT)of Yiqi Huoxue Chinese patent medicine in the treatment of angina pectoris of coronary heart disease(CHD)was searched until December 2019.By using stata15.1 software,the total clinical effective rate,the improvement rate of ECG,the improvement rate of angina pectoris,the attack frequency and duration of angina pectoris were taken as the outcome indicators for network meta analysis and mapping.Results:51 RCTs were included,including 9 kinds of traditional Chinese medicine.The results of network meta analysis showed that:in terms of clinical total effective rate,the order was Shexiang Baoxin Pill(78.2%)>xueshuanxinming tablet>Dengzhan Shengmai capsule>Shengui Capsule>Tongxinluo capsule>Tongmai Yangxin pill>Yangxin tablet>Shexiang Tongxin drop pill>Naoxintong capsule;the improvement of ECG was Tongmai Yangxin pill(85.2%)>Yangxin tablet>Dengzhan Shengmai capsule>Shexiang Tongxin drop pill>Shexiang Baoxin Pill>Tongxinluo gum Capsule>Shengui Capsule>Naoxintong capsule;in order to reduce the frequency and duration of angina pectoris,they are conventional Naoxintong capsule(88.6%)>Shengui Capsule>Tongmai Yangxin pill>Shexiang Baoxin Pill>xueshuanxinmingpian>Tongxinluo capsule>Shexiang Tongxin drop pill>Dengzhan Shengmai capsule;Shexiang Baoxin Pill(66.9%)>Dengzhan Shengmai capsule>Shexiang Tongxin drop pill>Tongxinluo capsule>xueshuanxinmingning capsule Tablet>Tongmai Yangxin pill.Conclusion:Traditional Chinese medicine combined with western medicine has obvious advantages in the treatment of angina pectoris.Shexiang Baoxin Pill,Dengzhan Shengmai capsule and Tongmai Yangxin pill can be given priority.

Guanxin Ⅱ (冠心Ⅱ号) for the Management of Coronary Heart Disease

This article presents an integrated overview of GuanxinⅡ(冠心Ⅱ号)regarding its quality control,pharmacokinetics,pharmacology,clinical studies,adverse events,dosage and administration,and its pharmacoeconomic assessment.It has been demonstrated that GuanxinⅡhas beneficial effects on coronary heart disease(CHD).The underlying mechanism was proved to be its anti-ischemic,anti-apoptotic,antioxidative, antiplatelet and anti-inflammatory effects,and so on.Tanshinol,hydroxysafflor yellow A and ferulic acid might be responsible for the cardioprotective effect of GuanxinⅡ.In terms of acquisition cost,GuanxinⅡis cheaper than other drugs currently available for CHD.GuanxinⅡis safe,cheap,and effective in the management of CHD.However,the mechanism of its cardioprotective effects has not been completely understood because of limitations in the research methodologies of Chinese medicine.Further work should be carried out with single components such as tanshinol,hydroxysafflor yellow A and ferulic acid,using modern biochemical and molecular methods.

Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease

Background Many young adults with moderate hyperlipidemia do not meet statin treatment criteria under the new American Heart Association/American College of Cardiology cholesterol guidelines because they focus on 10-year cardiovascular risk. We evaluated the association between years of exposure to hypercholesterolemia in early adulthood and future coronary heart disease （CHD） risk.